Cellosaurus cell line NT-18LM (CVCL

Cross-references
Cell line name	NT-18LM
Accession	CVCL_C4N5
Resource Identification Initiative	To cite this cell line use: NT-18LM (RRID:CVCL_C4N5)
Comments	Doubling time: 6.35 days (PubMed=36269546). Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
Sequence variations	Mutation; HGNC; HGNC:2681; DAXX; Simple; p.Cys629Leufs*29 (c.1884dupC); Zygosity=Unspecified (PubMed=36269546). Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Arg29Ter (c.85C>T); ClinVar=VCV000200970; Zygosity=Unspecified (PubMed=36269546). Mutation; HGNC; HGNC:11633; TCF3; Simple; p.Lys101Arg (c.302A>G); ClinVar=VCV000810990; Zygosity=Unspecified (PubMed=36269546).
Disease	Pancreatic neuroendocrine tumor G3 (NCIt: C172814) Neuroendocrine tumor of pancreas (ORDO: Orphanet_97253)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual	CVCL_C4N6 ! NT-18P CVCL_C4N7 ! NT-36
Sex of cell	Male
Age at sampling	56Y
Category	Cancer cell line
Publications	PubMed=36269546; DOI=10.1007/s13402-022-00727-z; PMCID=PMC9747820 Fabrice Viol, Bence Sipos, Martina Fahl, Till Sebastian Clauditz, Tania Amin, Malte Kriegs, Maike Nieser, Jakob Robert Izbicki, Samuel Huber, Ansgar W. Lohse, Jorg Schrader; Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. Cell. Oncol. (Dordr.) 45:1401-1419(2022)
Encyclopedic resources	Wikidata; Q116050014
Entry history
Entry creation	15-Dec-2022
Last entry update	19-Dec-2024
Version number	4